Hereditary Angioedema Market

Hereditary Angioedema Market, by Drug Class,
Distribution Channel, and Region - Global Trends
and Forecast till 2025
Hereditary angioedema (HAE) is a rare disorder related with the immune system. The lifethreatening condition is caused due to the lack of C1-esterase inhibitor (C1-INH) causing the
blood vessels to dilate. The symptoms of the disease include recurrent episodes of edema in
various body parts such as hands, feet, face and airways. HAE is classified into 3 types: Type I
HAE, Type II HAE and Type III HAE based on the reduction in its synthesis of inhibitor or the
formation of a dysfunctional protein. Although, the condition is hereditary, the absence of a
family history does not rule out the diagnosis of HAE, indicating that as many as 25% of HAE
cases result from a spontaneous mutation of the C1-inhibitor gene at conception.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1292
The global hereditary angioedema market was valued at US$ 1,563.7 million in 2016 and is
expected to witness a robust CAGR of 9.1% over the forecast period (2017 - 2025).
Market Dynamics
The major factor driving growth of the hereditary angioedema market include intense R&D
initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary
angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune
Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary
Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected
to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest
manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of
acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding
the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary
angioedema market growth.
Increasing prevalence and rising awareness of hereditary angioedema to augment market growth
The increasing number of hereditary angioedema cases and the hereditary nature giving the
disease an ability to pass the defective gene to the future generations is expected to propel
market growth. According to the survey by International Hereditary Angioedema Organization
(HAEi), 2015, the global prevalence of hereditary angioedema is estimated to be around 1 in
10,000 to 50,000 people, meaning that around a quarter million people suffer globally from this
rare and life threatening deficiency condition. Also, according to National Association for Rare
Disorders, 2016, the risk of passing the abnormal gene from affected parent to offspring is 50%
for each pregnancy regardless of the sex of the resulting child. North America dominates the
hereditary angioedema market, owing to the higher number of drugs approved in the regions,
presence of major manufacturers and the presence of various organizations serving HAE
patients. In 2017, the U.S. Food and Drug Administration (FDA) approved Haegarda (C1-esterase
inhibitor) manufactured by CSL Behring for routine prophylaxis to prevent HAE attacks in
adolescent and adult patients. However, the rare occurrence of the disease make it difficult for
efficient diagnosis and either opt for alternative therapies to control the disease, thus accounting
to be the major factors restraining the market growth.
Report includes chapters which deeply display the following deliverable about industry :
• Hereditary Angioedema Market Research Objective and Assumption
• Hereditary Angioedema Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Hereditary Angioedema Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Hereditary Angioedema Market, By Regions
• Hereditary Angioedema Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Hereditary Angioedema Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Hereditary Angioedema Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Hereditary Angioedema Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1292
Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst
Pharmaceuticals,
Inc.,
Ionis
Pharmaceuticals,
Arrowhead
Pharmaceuticals,
Adverum
Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Download Report